Enveric welcomes final FDA guidance on psychedelic drug trials

• Enveric Biosciences welcomed the FDA’s finalized guidance for clinical investigations of psychedelic and psychedelic-inspired therapeutics, calling it a clearer roadmap without lower standards.
• CEO Joseph Tucker cited key hurdles flagged by FDA, including functional unblinding, patient monitoring, abuse potential, repeat dosing, psychotherapy’s role.
• Enveric said its EB-003 is designed to drive neuroplasticity-related signaling while avoiding hallucinations, which could support conventional blinded trials.
• The company said a non-hallucinogenic profile could reduce supervision needs, limit psychotherapy confounding, support a more scalable outpatient model.
• Enveric said its planned Phase 1 program for EB-003 will assess safety, tolerability, pharmacokinetics, subjective effects, biomarkers across single, repeat dosing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607280800BIZWIRE_USPR_____20260728_BW654467) on July 28, 2026, and is solely responsible for the information contained therein.